Literature DB >> 3083857

An immunohistochemical study of the incidence and significance of human gonadotrophin and prolactin binding sites in normal and neoplastic human ovarian tissue.

A Al-Timimi, C H Buckley, H Fox.   

Abstract

An immunoperoxidase technique has been utilised for the demonstration of follicle stimulating hormone (FSH), luteinising hormone (LH) and prolactin (PRL) binding sites in normal human ovaries and in a wide range of benign and malignant epithelial tumours of the ovary. The incidence of FSH, LH and PRL binding was, respectively, 32%, 41% and 39% in normal ovaries, 30%, 18.5% and 22.5% in benign epithelial tumours and 51%, 32% and 43% in malignant epithelial neoplasms. The incidence of FSH binding was significantly higher in malignant epithelial neoplasms than in either normal ovaries or benign epithelial tumours but otherwise no correlation was found between hormone binding capacity and the degree of malignancy of epithelial ovarian tumours, the histological type of the tumour, the degree of differentiation of the malignant epithelial tumours or the presence or absence of metastatic disease. Well differentiated malignant tumours did, however, tend to stain more strongly than did poorly differentiated neoplasms, thus suggesting that the number of binding sites per cell tends to decrease with decreasing degrees of differentiation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3083857      PMCID: PMC2001355          DOI: 10.1038/bjc.1986.55

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Immunohistochemical studies of prolactin binding in sex accessory organs of the male rat.

Authors:  R J Witorsch
Journal:  J Histochem Cytochem       Date:  1978-07       Impact factor: 2.479

2.  Subcellular localization of gonadotropins and testosterone in the developing fetal rat testis.

Authors:  G V Childs; C Hon; L R Russell; P J Gardner
Journal:  J Histochem Cytochem       Date:  1978-07       Impact factor: 2.479

3.  Light microscopic localization of binding sites for human chorionic gonadotrophin in luteinized rat ovaries by a peroxidase-labeled antibody method.

Authors:  P Petrusz; A Uhlarik
Journal:  J Histochem Cytochem       Date:  1973-03       Impact factor: 2.479

4.  Immunoreactive prolactin in epithelial cells of normal and cancerous human breast and prostate detected by the unlabeled antibody peroxidase-antiperoxidase method.

Authors:  D M Purnell; E A Hillman; B M Heatfield; B F Trump
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

5.  Cytochemistry of sex steroid receptors: a critique.

Authors:  K S McCarty; D S Reintgen; H F Seigler; K S McCarty
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

6.  Immunocytochemical and autoradiographic demonstration of prolactin binding to human breast cancer cells in tissue culture.

Authors:  J A Paterson; H Salih; R P Shiu
Journal:  J Histochem Cytochem       Date:  1982-02       Impact factor: 2.479

7.  Immunocytochemical localization of prolactin binding sites in mouse adrenal gland.

Authors:  L B McDonough; J E Ewig
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1982

8.  Intracellular prolactin in rat corpus luteum and adrenal cortex.

Authors:  J M Nolin
Journal:  Endocrinology       Date:  1978-02       Impact factor: 4.736

9.  Intracellular localization of prolactin receptor and prolactin in the rat ovary by immunocytochemistry.

Authors:  A E Dunaif; E A Zimmerman; H G Friesen; A G Frantz
Journal:  Endocrinology       Date:  1982-05       Impact factor: 4.736

10.  Prolactin receptors in human breast tumors.

Authors:  L Turcot-Lemay; P A Kelly
Journal:  J Natl Cancer Inst       Date:  1982-03       Impact factor: 13.506

View more
  2 in total

1.  Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Authors:  Alfredo Perales-Puchalt; Nikolaos Svoronos; Melanie R Rutkowski; Michael J Allegrezza; Amelia J Tesone; Kyle K Payne; Jayamanna Wickramasinghe; Jenny M Nguyen; Shane W O'Brien; Kiranmai Gumireddy; Qihong Huang; Mark G Cadungog; Denise C Connolly; Julia Tchou; Tyler J Curiel; Jose R Conejo-Garcia
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

Review 2.  Clinical applications of hormonal therapy in ovarian cancer.

Authors:  Gautam G Rao; David S Miller
Journal:  Curr Treat Options Oncol       Date:  2005-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.